



Scan and Explore!

Strand's AI-Powered Single Cell RNA Portal:

Refining Precision Research,
One Cell at a Time



Scan to log in to scRNA data curation portal.

We aim to establish an integrated platform that supports the entire drug discovery workflow, from the early stages of target discovery and validation through to the late stages of clinical trial support and patient stratification.


The Challenge: Data Heterogeneity Crisis

- Siloed data and inconsistent metadata make public scRNA-seq datasets difficult to compare or integrate, limiting target discovery.
- Lack of harmonization in terminologies, classifications, and identifiers across datasets complicates large-scale and integrative analyses.
- Integration across studies can dilute fine cell-type resolution, reducing accuracy and interpretability.
- Manual curation is slow and error-prone, delaying research onset as scientists must source datasets, fill gaps, and interpret raw data before moving forward.



Our Solution


Our proposed unified platform delivers AI-powered metadata harmonization and data analysis, bringing consistency across single-cell, bulk, and proteomics datasets. It provides secure pipelines for analyzing both public and in-house data, while integrating AI tools for annotation, integration, perturbation, and response prediction. The platform supports end-to-end discovery workflows, with applications in target discovery, biomarker identification, and translational research.



1. Metadata Harmonization


i) Data Harnessing, Standardization and Harmonization:

- Strand has developed a data showcase for scRNAseq datasets with extensive metadata schema and standardized ontologies that can significantly cut down the time, effort, and error associated with each step.
- The showcase focuses on diseases with significant unmet clinical needs like Ulcerative Colitis, Alzheimer's Disease, Frontotemporal Dementia, etc.
- Public datasets, such as those from Gene Expression Omnibus (NCBI), are first harnessed and then meticulously curated and harmonized, with quality control processes applied separately to both stages, using a mix of automation and manual review.
- Turnaround time of 1-2 days.



Key Features:

- Our datasets have **80+** unique metadata fields organized at 3 levels of curation - study (11), experiment (35+), and sample (34+) levels.
- **19** metadata fields use controlled vocabulary and **21** metadata fields use defined ontologies.
- Our portal is equipped with **32** key filters that enable users to set attributes, categories, and values which can pick out relevant datasets within seconds.
- Well organized documentation section with clearly defined SOPs.
- Key metrics of the metadata can be visualized using bar graphs, pie charts and line graphs, and visualizations can be exported by users for easy and effective communication.
- Our showcase, updated monthly, currently contains datasets for Ulcerative Colitis, Alzheimer's disease and Frontotemporal dementia. Other disease types such as Parkinson's disease and Crohn's disease are in the pipeline.






Example Showcase 1

Ulcerative Colitis (UC)

- Ulcerative Colitis is a chronic inflammatory disease with no available treatments for cure at this time. But RNAseq based studies are uncovering the cellular pathways that may be involved in disease pathogenesis.
- Our Ulcerative Colitis showcase currently hosts **43 million** cells, **1,814** samples, **106** distinct cell types, **35** different tissue types, **120+** metadata fields, and **89** datasets, sourced from NCBI's GEO platform.
- About **884** non-inflamed samples and **1002** inflamed samples are included, allowing meaningful comparisons between the two states.
- The samples are primarily from gut tissues, with a few from blood, altogether accounting for 106 unique cell types.

Our showcase with deep metadata enables phenotype-specific exploration



Example Showcase 2

Alzheimer's Disease (AD)

- Alzheimer's disease is a progressive, neurodegenerative disorder that gradually impairs memory, cognition, and daily functioning as neurons are damaged and die. Over 416 million people globally are believed to be on the AD continuum.
 - There is currently no cure, and disease pathogenesis is not clearly understood.
- Its genetic and molecular pathways are being increasingly investigated using scRNA seq studies.
- Our portal showcases **10 million** cells, **1,161** samples, **64** distinct cell types, **24** different tissue types, **120+** metadata fields, **78** studies, and **2** model organisms, sourced from NCBI's GEO platform.



	UC Showcase	AD Showcase	Parkinson's Disease (PD) Showcase:
 DATASETS	89 sourced from GEO	78 sourced from GEO	13 sourced from GEO
 SAMPLES	1814*	1161*	192
 CELLS CURATED	43 million	10 million	0.63 million
 UNIQUE CELL TYPES	106	64	25
 TISSUE TYPES	35	24	6
 METADATA TYPES	120+	120+	85+

**including 884 non-inflamed and 1002 inflamed samples*

ii) RAG-LLM Metadata Curation Tool: AI-Powered Automation for Large-Scale Metadata Harmonization

We developed a RAG-based LLM method for automated metadata ingestion, using our portal's curated metadata as the ground truth for evaluation. This tool streamlines the process by allowing users to curate metadata fields with a single click.

Highlights:

- **One-click curation** of complex metadata fields
- Achieves **95%+ accuracy** in disease term classification
- **3× faster** turnaround time vs. manual methods
- Adaptable across diverse disease areas

2. Analysis Pipelines

i) scRNA Sequencing Pipeline: Comprehensive End-to-End Pipeline for Transcriptomic Exploration

Our single-cell analysis platform enables quick onboarding of new datasets, with data showcases updated monthly. Users can bring their own datasets and analyze

them alongside public datasets in a secure cloud environment, while ensuring that cellular granularity is preserved throughout integrative analysis.

Highlights:

- Raw data QC, normalization, and clustering with batch correction
- Cell-type annotation powered by AI and curated reference data
- Bring-your-own-data integration with curated public datasets
- Maintains cellular granularity for accurate disease modeling



ii) Post-Translational Modifications (PTM) Pipeline: A High-Resolution Proteomics Workflow for Deeper Biological Insights

Our platform supports PTM identification and annotation, enables differential analysis across conditions, and provides pathway analysis to explore potential targets.

Highlights:

- Identification and quantification of PTM peptides via tandem MS/MS data
- Differential analysis across disease and control conditions
- Pathway mapping to highlight potential druggable targets
- Complements scRNA-based insights with proteomic precision

Case Study: Ulcerative Colitis and Vedolizumab Response

Ulcerative Colitis (UC) is a chronic inflammatory disease that lowers quality of life and raises colorectal cancer risk. Vedolizumab (VDZ), a gut selective antibody to $\alpha 4\beta 7$ integrin, is widely used, yet nearly half of patients do not respond, underscoring the need for predictive biomarkers.

Using Strand's scRNA portal, we integrated two published studies with over 170,000 cells from blood and intestinal biopsies. Harmonization, QC, clustering, annotation, and differential expression were performed entirely within the portal. The analysis revealed a few blood-based markers potentially associated with VDZ response, showing how the portal enables cross-study integration, high-resolution profiling and clinically-relevant insights.

3. AI Toolkit

A Suite of Tools Designed to Accelerate Drug Target Discovery

The AI toolkit is a suite of tools built on single-cell foundation models to address bottlenecks in drug target discovery. It automates metadata ingestion and harmonization, supports annotation


and dataset integration, and includes perturbation and response prediction while preserving cellular granularity. It is designed for target discovery, biomarker identification, and translational research.

Our AI toolkit brings together:

- RAG-based LLM method for automated metadata ingestion
- AI tools for annotation, integration, perturbation, and response prediction
- Standardized metadata across single-cell, bulk, and proteomics datasets
- Secure pipelines for analyzing public and in-house data



AI Toolkit in Action: From Annotation to Actionable Insights




Highlights of our AI toolkit include:

- Fine-tuned scBERT and scGPT models for accurate cell-type annotation
- Ensemble predictions that flag rare or novel cell types
- Supports hypothesis generation, biomarker discovery, and target validation
- Seamless integration with curated scRNA datasets

Applications

- Enhances data discovery and accessibility across diverse datasets
- Facilitates analysis for downstream research including biomarker discovery, patient stratification, and drug repurposing
- Supports machine learning, large language models, and AI-driven applications



Key use cases include:

- Patient stratification
- Clinical trial design
- Target discovery
- Drug response prediction

What Sets Us Apart:

- Showcase of disease-specific public datasets with **deep metadata**
- Metadata curation pipeline with **LLM automation**
- **Comprehensive AI tools** purpose-built for target discovery
- Proteomics, workflows for PTM and **differential expression analysis**
- **Quick** dataset onboarding
- **Monthly update** of our data showcase

25⁺

YEARS OF
EXPERIENCE

80,000+

Genetic
Tests
Reported

500+

Projects
Executed for
Genomics
Majors Globally

Presence in
20+
Countries



strand 

📍 7th Floor, MSR North Tower, #144, Outer Ring Road, Nagavara, Bengaluru - 560045

📞 +91 9980448044

✉️ hello@strandls.com

🌐 strandls.com